Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? Perhaps your project could be the key [...]
About Lucy TuffinThis author has not yet filled in any details.
So far Lucy Tuffin has created 74 blog entries.
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart FailureLucy Tuffin2020-01-13T12:28:50+00:00
DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to develop novel gene ther [...]
A FVIII gene therapy treatment, developed by world leading gene therapy expert, Professor Amit Nathwani at UCL has shown positive results in treating patients w [...]
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has made an $ [...]
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cellsLucy Tuffin2019-12-17T11:56:35+00:00
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Techn [...]
BioMarin today announced it has submitted a marketing application to the European Medicines Agency (EMA), for the investigational gene therapy, valoctocogene ro [...]
UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept funding. The initiative will [...]
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic LeukemiaLucy Tuffin2019-11-11T15:49:36+00:00
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation program [...]
The launch of Portico Ventures sees the introduction of two new models for intellectual property (IP) commercialisation to support UCL staff who have created no [...]
UCLB has concluded an exclusive agreement to license a collection of pre-clinical small molecule compounds for the treatment of alpha-1-antitrypsin deficiency w [...]